IQVIA Q4 Revenue Up 10.3% to $4.36B; Price Targets Slashed
IQVIA reported Q4 revenue up 10.3% to $4.36 billion with adjusted EPS rising 9.6% to $3.42, while its R&D backlog reached $32.7 billion and book-to-bill ratio hit 1.18x. Mizuho cut its price target to $215 and Truist lowered its forward EBITDA multiple to 13x, trimming its target to $245.
1. Q4 Performance Highlights
IQVIA reported Q4 revenue of $4.36 billion, a 10.3% increase driven by strength in clinical research services and commercial analytics. Adjusted EPS rose 9.6% to $3.42, while R&D backlog reached $32.7 billion and the book-to-bill ratio stood at 1.18x.
2. Analyst Price Target Revisions
Mizuho lowered its price target from $266 to $215 and reiterated an Outperform rating, reflecting cautious sentiment on AI integration. Truist cut its forward EBITDA multiple from 14x to 13x and trimmed its price target from $290 to $245, while maintaining a Buy rating.
3. Forward Guidance and AI Headwinds
IQVIA forecasts full-year revenue of $17.15–$17.35 billion and adjusted EPS of $12.55–$12.85, incorporating re-segmentation effects from AI integration. Analysts warn that AI headwinds and segmentation changes could weigh on future margins and valuation multiples.